Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 65 - 72 of 12007 results

FTC Chair Ferguson Tells Congress Agency Needs Extra Resources to Enforce AI Deepfake Act, and Trump Signs Nuclear Energy EO — AI: The Washington Report

May 29, 2025| Article| Viewpoint

Why You Should Learn the Playbook: Know the Game Plan for Distressed Acquisitions and Divestitures, Part Four—Regulatory Compliance and Related Issues in Distressed Health Care Transactions

May 29, 2025| News

Republicans Using 'Unusual' Antitrust Argument in Asset Manager Lawsuit

May 28, 2025| News

PBM Legislation in the Reconciliation Bill is Far From Sweeping PBM Reform

May 28, 2025| Blog| Viewpoint

New York Department of Health Publishes Material Transactions Reporting Form

May 28, 2025| Blog| Viewpoint

CMMI Unveils New Strategic Direction: Preventive Care, Patient Empowerment, and Competition

May 27, 2025| Blog| Viewpoint

Practical Policies – When Should You Hire an Employment Lawyer?

May 27, 2025| Podcast| Viewpoint

Federal Contractors Need New DEI Diligence Before Cutting Deals

May 23, 2025| News

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases